{"page_content": "Improve Human Health \nMeeting the unmet medical needs of patients\nImproving human health is our biggest ambition and that is why it is the \nfirst pillar in our Trust for Life strategy. Our success relies on meeting the unmet medical needs of patients. That\u2019s why we\u2019re focused on marketing our four commercial products \u2013 ZEJULA, Optune, QINLOCK, and NUZYRA \u2013 scaling our capabilities, and developing our portfolio and product candidates to expand the availability of treatments for patients in need. \nBy identifying three targets to achieve our goal, we can more steadily \nprogress toward reaching one million new patients by 2030. Our route toward improving human health includes accelerating medicines to patients, expanding our pipeline, and focusing on technology.\nAccelerating Medicines to Patients\nHelping more people access our potential best-in-class and first-in-class products.\nExpanding our Pipeline\nGrowing our product pipeline through collaborative partnerships and corporate development.\nFocusing on Technology\nLeveraging technology to drive innovation in human health.\nBy 2030, Zai Lab expects to reach more than \none million new patients. We seek to achieve this goal by increasing access to patients for our existing commercial products and progressing our pipeline to commercialization.\nOur commercial organization has bold ambitions, In \nthe near term, we aim to become the market leader in China for ZEJULA, Optune, and QINLOCK and set a solid foundation for future success. In the medium term, we are preparing for 8 additional product launches in Greater China. And in the long term, we want to establish therapeutic area leadership in both China and the  United States.\u201d  \n\u2013 William Liang, Chief Commercial Officer, President, Greater China\n10", "metadata": {"source": "NASDAQ_ZLAB_2022.pdf", "page": 9, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}